Mexico City – Mexico is experiencing a significant boost to its economy and healthcare sector, with four major pharmaceutical companies announcing investments of over 12 billion pesos (approximately $641.45 million USD). The news was shared last Thursday at President Claudia Sheinbaum’s morning press conference, highlighting the country’s growing appeal as a hub for pharmaceutical innovation and manufacturing.
The companies – Boehringer Ingelheim, Carnot Laboratorios, Bayer, and AstraZeneca – all confirmed their commitment to expanding operations, creating thousands of new jobs, and strengthening Mexico’s role in global healthcare.
Companies Detail Expansions and Job Creation
Boehringer Ingelheim, a German pharmaceutical giant, is set to invest 3.5 billion pesos. This will be used to transform its Mexico City tablet production facility into the company’s largest worldwide. The plant in Xochimilco aims to produce 5 billion pills annually, supplying anti-hypertensive and anti-diabetic medications to the local market and exporting to over 40 countries. This investment is expected to create 1,800 direct, and more than 15,000 indirect, jobs.
Mexican company Carnot Laboratorios is also investing 3.5 billion pesos over the next five years to build a new, state-of-the-art production plant in Villa de Tezontepec, Hidalgo. This facility will serve as a strategic center for manufacturing and biotechnology, with the capacity to export medications to over 30 countries. The project will generate 600 highly specialized direct jobs and at least 5,000 indirect jobs.
Bayer, another German multinational, is committing 3 billion pesos over the next five years to enhance its 14 sites across Mexico. Funds will be allocated to increase the production of active pharmaceutical ingredients in Veracruz, add new medication production lines in the State of Mexico, and expand its biological fungicide plant in Tlaxcala. Additionally, Bayer will triple its investment in clinical studies within Mexico, which will provide Mexicans faster access to innovative medicines.
Finally, British-Swedish company AstraZeneca is investing 2.25 billion pesos over the next two years. A significant portion of this will go toward clinical research and expanding its Global Innovation and Technology Center in Guadalajara. The company will also grow its essential medication production plant in Naucalpan, State of Mexico, creating 600 direct jobs and 2,500 indirect jobs.
Government Leaders Praise the Initiative
Economy Minister Marcelo Ebrard described the current period as a “time of great transformation” for the health sector, driven by the confidence of both national and international investors in the government’s economic initiatives. He noted that the projects promote innovation, strengthen the manufacturing industry, and position Mexico as a regional leader in pharmaceuticals and medical devices.
Health Secretary David Kershenobich Stalnikowitz emphasized that the development of Mexico’s pharmaceutical sector is a “high priority” for President Sheinbaum. He noted that these investments will foster innovation, expand clinical research, and digitize processes, marking a period of positive transformation for Mexico’s health sector.
These new investments are part of the broader “Plan México,” which aims to boost domestic production across various sectors and reduce the country’s reliance on imports. This effort follows a similar announcement last month where four other Mexican pharmaceutical companies committed to investments totaling over 13 billion pesos.
We Need Your Support: While other local media outlets have retreated behind paywalls, at Banderas News, we believe news should be free for everyone. Would you help us provide essential information to our readers at no cost? We can’t do it without you. Your contribution helps us sustain and grow.